BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11836045)

  • 21. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone density effects of continuous estrone sulfate and varying doses of medroxyprogesterone acetate. Ogen/Provera Study Group.
    Nand SL; Wren BG; Gross BA; Heller GZ
    Obstet Gynecol; 1999 Jun; 93(6):1009-13. PubMed ID: 10362172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women.
    Meschia M; Brincat M; Barbacini P; Maini MC; Marri R; Crosignani PG
    Eur J Obstet Gynecol Reprod Biol; 1992 Oct; 47(1):53-7. PubMed ID: 1330761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT.
    Rosen HN; Parker RA; Greenspan SL; Iloputaife ID; Bookman L; Chapin D; Perlmutter I; Kessel B; Qvist P; Rosenblatt M
    Calcif Tissue Int; 2004 May; 74(5):415-23. PubMed ID: 14961215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
    Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
    Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-ischemic effect of chronic oestrogen replacement therapy alone or in combination with medroxyprogesterone acetate in different replacement schemes.
    Cerquetani E; Leonardo F; Pagnotta P; Galetta P; Onorati D; Fini M; Rosano GM
    Maturitas; 2001 Sep; 39(3):245-51. PubMed ID: 11574184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen.
    Ongphiphadhanakul B; Piaseu N; Tung SS; Chailurkit L; Rajatanavin R
    Maturitas; 2000 Feb; 34(2):179-84. PubMed ID: 10714913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group.
    Archer DF; Pickar JH; Bottiglioni F
    Obstet Gynecol; 1994 May; 83(5 Pt 1):686-92. PubMed ID: 8164926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
    Mizunuma H; Okano H; Soda M; Kagami I; Miyamoto S; Tokizawa T; Honjo S; Ibuki Y
    Maturitas; 1997 May; 27(1):69-76. PubMed ID: 9158080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis.
    Grey AB; Cundy TF; Reid IR
    Clin Endocrinol (Oxf); 1994 May; 40(5):671-7. PubMed ID: 8013147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum estradiol concentration as measured by HPLC-RIA and bone mineral density in postmenopausal women during hormone replacement therapy.
    Yasui T; Uemura H; Umino Y; Takikawa M; Kuwahara A; Saito S; Matsuzaki T; Maegawa M; Furumoto H; Miura M; Irahara M
    Horm Res; 2004; 61(3):117-25. PubMed ID: 14676459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women.
    Armamento-Villareal RC; Napoli N; Klug T; Civitelli R
    Bone; 2004 Sep; 35(3):682-8. PubMed ID: 15336604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone protection for early menopausal women in China: standard or half-dose estrogen with progestin? A one-year prospective randomized trail.
    Zhu SY; Deng Y; Wang YF; Xue W; Ma X; Sun A
    Gynecol Endocrinol; 2019 Feb; 35(2):165-169. PubMed ID: 30449208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison.
    Pan HA; Wang ST; Pai MC; Chen CH; Wu MH; Huang KE
    J Reprod Med; 2003 May; 48(5):375-80. PubMed ID: 12815913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
    Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
    N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques.
    Cline JM; Soderqvist G; von Schoultz E; Skoog L; von Schoultz B
    Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):93-100. PubMed ID: 8572040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.